Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis.
暂无分享,去创建一个
J. Ringe | P. Marie | T. Häupl | H. Miraoui
[1] E. Wolf,et al. High Cortical Bone Mass Phenotype in Betacellulin Transgenic Mice Is EGFR Dependent , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] K. Moriyama,et al. Fibroblast Growth Factor Receptor 2 Promotes Osteogenic Differentiation in Mesenchymal Cells via ERK1/2 and Protein Kinase C Signaling* , 2009, Journal of Biological Chemistry.
[3] E. Wardelmann,et al. Sustained Platelet-Derived Growth Factor Receptor α Signaling in Osteoblasts Results in Craniosynostosis by Overactivating the Phospholipase C-γ Pathway , 2008, Molecular and Cellular Biology.
[4] S. Fitter,et al. Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.
[5] T. Patel,et al. A Novel Role of Sprouty 2 in Regulating Cellular Apoptosis* , 2008, Journal of Biological Chemistry.
[6] J. Cornish,et al. Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell‐Dependent Mechanisms , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] A. Wilkie. Cancer drugs to treat birth defects , 2007, Nature Genetics.
[8] X. Coumoul,et al. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis , 2007, Nature Genetics.
[9] C. Kaps,et al. Gene Expression Profiling of Rheumatoid Arthritis Synovial Cells Treated with Antirheumatic Drugs , 2007, Journal of biomolecular screening.
[10] V. P. Eswarakumar,et al. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis , 2006, Proceedings of the National Academy of Sciences.
[11] G. Morriss-Kay,et al. A model for the pharmacological treatment of crouzon syndrome. , 2006, Neurosurgery.
[12] A. Wilkie. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. , 2005, Cytokine & growth factor reviews.
[13] D. Ambrosetti,et al. Mechanisms underlying differential responses to FGF signaling. , 2005, Cytokine & growth factor reviews.
[14] V. P. Eswarakumar,et al. Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.
[15] D. Ambrosetti,et al. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation , 2005, The Journal of cell biology.
[16] Joseph Schlessinger,et al. Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors , 2004, Science.
[17] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[18] J. Lemonnier,et al. Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation* , 2004, Journal of Biological Chemistry.
[19] L. Khachigian,et al. Fibroblast Growth Factor-2 Represses Platelet-derived Growth Factor Receptor-α (PDGFR-α) Transcription via ERK1/2-dependent Sp1 Phosphorylation and an Atypical cis-Acting Element in the Proximal PDGFR-α Promoter* , 2004, Journal of Biological Chemistry.
[20] G. Guy,et al. Tyrosine Phosphorylation of Sprouty2 Enhances Its Interaction with c-Cbl and Is Crucial for Its Function* , 2003, Journal of Biological Chemistry.
[21] H. Ryoo,et al. Erk pathway and activator protein 1 play crucial roles in FGF2‐stimulated premature cranial suture closure , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.
[22] Ivan Dikic,et al. Negative receptor signalling. , 2003, Current opinion in cell biology.
[23] E. Wagner,et al. Functions of AP1 (Fos/Jun) in bone development , 2002, Annals of the rheumatic diseases.
[24] E. Nishida,et al. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway , 2002, Nature Cell Biology.
[25] Boon Chuan Low,et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling , 2002, The EMBO journal.
[26] P. Marie,et al. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. , 2002, Genes & development.
[27] I. Lax,et al. FRS2α attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Tsygankov,et al. Beyond the RING: CBL proteins as multivalent adapters , 2001, Oncogene.
[29] M. Mohammadi,et al. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Lemonnier,et al. Role of N‐Cadherin and Protein Kinase C in Osteoblast Gene Activation Induced by the S252W Fibroblast Growth Factor Receptor 2 Mutation in Apert Craniosynostosis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] J. Lemonnier,et al. Increased Expression of Protein Kinase Cα, Interleukin‐1α, and RhoA Guanosine 5′‐Triphosphatase in Osteoblasts Expressing the Ser252Trp Fibroblast Growth Factor 2 Apert Mutation: Identification by Analysis of Complementary DNA Microarray , 2001 .
[32] W. Langdon,et al. Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.
[33] D. Ornitz,et al. Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. Waksman,et al. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[35] L A Opperman,et al. Cranial sutures as intramembranous bone growth sites , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[36] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[37] T. Hunter,et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.
[38] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[39] J. Heath,et al. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. , 1998, Human molecular genetics.
[40] B. Druker,et al. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Kool,et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.
[42] E. Jabs. Toward understanding the pathogenesis of craniosynostosis through clinical and molecular correlates , 1998, Clinical genetics.
[43] A. Wilkie. Craniosynostosis: genes and mechanisms. , 1997, Human molecular genetics.
[44] D. Graves,et al. Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures. , 1997, The American journal of physiology.
[45] Tait S. Smith,et al. The effect of systemically administered PDGF‐BB on the rodent skeleton , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[46] R. Shiekhattar,et al. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. , 1995, Genomics.
[47] E. Canalis,et al. Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. , 1992, The Journal of clinical investigation.
[48] M. Karin,et al. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.
[49] P. Marie,et al. Effects of epidermal growth factor on bone formation and resorption in vivo. , 1990, The American journal of physiology.
[50] E. Canalis,et al. Platelet-derived growth factor enhances deoxyribonucleic acid and collagen synthesis in osteoblast-enriched cultures from fetal rat parietal bone. , 1989, Endocrinology.
[51] J. Bergeron,et al. In vivo demonstration of cell types in bone that harbor epidermal growth factor receptors. , 1988, Endocrinology.
[52] M. M. Cohen. Perspectives on Craniosynostosis. , 1980, The Western journal of medicine.
[53] P. Marie,et al. Roles of FGFR2 and twist in human craniosynostosis: insights from genetic mutations in cranial osteoblasts. , 2008, Frontiers of oral biology.
[54] G. Karsenty,et al. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. , 2006, Current topics in developmental biology.
[55] J. Licht,et al. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.
[56] G. Guy,et al. Regulator of epidermal growth factor signaling: Sprouty. , 2006, Methods in molecular biology.
[57] R. Baron,et al. Wnt signaling: a key regulator of bone mass. , 2006, Current topics in developmental biology.
[58] C. Vinson,et al. Molecular Medicine © 2000 The Picower Institute Press Activator Protein-1 Mediates Induced but not Basal Epidermal Growth Factor Receptor Gene Expression , 1999 .